All > Pancreatic Cancer

Spartalizumab for Pancreatic Cancer Metastatic

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pancreatic Cancer Metastatic+1 MoreSpartalizumab - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a combination of two monoclonal antibodies to treat pancreatic cancer. Monoclonal antibodies are drugs that interfere with the ability of tumors cells to grow and spread.

Eligible Conditions
  • Pancreatic Cancer Metastatic
  • Stage IV Pancreatic Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Cobimetinib
1
Calaspargase Pegol-mknl
1
SD-101

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Up to 2 years from study start

Year 2
Overall survival time
Progression-free survival
Response duration
Year 2
Overall response rate (ORR)
Week 6
Maximal tolerated dose (MTD) of siltuximab that can be combined with spartalizumab

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Cobimetinib
1
Calaspargase Pegol-mknl
1
SD-101

Trial Design

4 Treatment Groups

Treatment spartalizumab and siltuximab phase I level 2a
1 of 4
Treatment spartalizumab and siltuximab phase II
1 of 4
Treatment spartalizumab and siltuximab Phase I level 2
1 of 4
Treatment spartalizumab and siltuximab Phase I dose level 1
1 of 4

Experimental Treatment

42 Total Participants · 4 Treatment Groups

Primary Treatment: Spartalizumab · No Placebo Group · Phase 1 & 2

Treatment spartalizumab and siltuximab phase I level 2aExperimental Group · 2 Interventions: Spartalizumab, Siltuximab · Intervention Types: Biological, Biological
Treatment spartalizumab and siltuximab phase IIExperimental Group · 2 Interventions: Spartalizumab, Siltuximab · Intervention Types: Biological, Biological
Treatment spartalizumab and siltuximab Phase I level 2Experimental Group · 2 Interventions: Spartalizumab, Siltuximab · Intervention Types: Biological, Biological
Treatment spartalizumab and siltuximab Phase I dose level 1Experimental Group · 2 Interventions: Spartalizumab, Siltuximab · Intervention Types: Biological, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Spartalizumab
Not yet FDA approved
Siltuximab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years from study start

Who is running the clinical trial?

NovartisIndustry Sponsor
1,585 Previous Clinical Trials
2,702,718 Total Patients Enrolled
EUSA Pharma, Inc.Industry Sponsor
4 Previous Clinical Trials
1,255 Total Patients Enrolled
Emory UniversityLead Sponsor
1,509 Previous Clinical Trials
2,706,127 Total Patients Enrolled
Bassel El-Rayes, MD2.84 ReviewsPrincipal Investigator - Emory University
Emory University
6 Previous Clinical Trials
97 Total Patients Enrolled
1Patient Review
This oncologist is very difficult to get in touch with and follow up with. I would not recommend.

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
A person's platelet level is considered normal if it is ≥ 75 x 109/L.
Aspartate transaminase (AST) ≤ 2.5 times the upper limit of normal, except for patients with liver metastasis, who may only be included if AST ≤ 5.0 times the upper limit of normal.
ALT levels ≤ 2.5 times the upper limit of the normal range (ULN) are acceptable, except for patients with liver metastasis, who may only have ALT levels ≤ 5.0 times the ULN.
The patient has a good prognosis and a relatively low level of disability.
The disease is an advanced form of pancreatic cancer that has failed to respond to at least one prior treatment with a standard regimen, such as gemcitabine and nab-paclitaxel, or folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX).
, direct bilirubin ≤ 0.3 x ULN, and conjugated bilirubin ≤ 0.1 x ULN
is required The text is saying that in order to be eligible for the study, you must have measurable disease according to the RECIST criteria.
A person's blood has absolute neutrophil count if it contains at least 1.5x 109 white blood cells per liter.
Hemoglobin (Hgb) ≥ 9 g/dL.
If the serum creatinine level is less than 1.5 mg/dL or the creatinine clearance is greater than or equal to 45 mL/min using the Cockcroft-Gault formula, the person has kidney function within the normal range.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top